Ticker Update

Class 3 Recall - Easyhaler Salbutamol

Orion Corporation T/A Orion Pharma (UK) Ltd are recalling the below batches as a precautionary measure due to an issue related to moulding defects in the bulk chambers where the inhalation powder is stored. There is a risk that the defect possibly presents as a hole in the bulk chamber resulting in the minor loss of inhalation powder. The manufacturer has confirmed that the devices will continue to function correctly with no impact on patient safety

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-easyhaler-salbutamol-sulfate-100-micrograms-per-actuation-slash-200-micrograms-per-actuation-inhalation-powder-el-21-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications&utm_source=43302c1f-c2f7-4a15-ace9-ad4630bf5c67&utm_content=immediately

Further Information

For more information or medical information queries, please contact: UK.MedicalInformation@orionpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 01/06/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

FIELD SAFETY NOTICE - AQUACEL EXTRA 15CMSQ

ConvaTec are voluntarily initiating a field action for the below-stated product because in some instances dressing has been found attached to the seam of the primary packaging therefore breaching the sterile barrier and making the product unable to be used.  Using a non-sterile device on a patient may potentially expose the patient to infectious agents

MHRA drug alert link: N/A

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 16/05/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

CLASS 3 RECALL - CLONIDINE HYDROCHLORIDE 50MICROGRAMS/5ML ORAL SOLUTION

SyriMed are recalling the below batch as a precautionary measure due to an issue related to the container closure (child-lock cap). The Marketing Authorisation Holder has received a number of complaints related to defective container closures and the investigation has identified an issue with the bottle capping during the manufacturing process for this batch only

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-syrimed-clonidine-hydrochloride-50micrograms-slash-5ml-oral-solution-el-21-a-slash-05?utm_medium=email&utm_campaign=govuk-notifications&utm_source=9d29e170-51bd-475e-b98c-3e284cb06be1&utm_content=immediately   

Further Information

For more information or medical information queries, please contact: customer.services@syrimed.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 16/05/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

CLASS 2 RECALL - MIDABUC - MIDAZOLAM (AS HCL) 10MG/ML OROMUCOSAL SOLUTION

: Eaststone Limited has informed us of an issue related to underfilled or empty bottles for MidaBuc - Midazolam (as HCL) 10mg/mL Oromucosal Solution. The below batch is being recalled as a precautionary measure following customer complaints

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-eaststone-limited-midabuc-midazolam-as-hcl-10mg-slash-ml-oromucosal-solution-el-21-a-slash-04?utm_medium=email&utm_campaign=govuk-notifications&utm_source=08ba5ead-1c0a-467b-b061-951a4cff9bb4&utm_content=immediately

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

Further Information

For more information or medical information queries please contact Eaststone at specials@eaststone.co.uk or alternatively call 0800 678 3102.

Class 4 Drug Caution in use - AMBISOME LIPOSOMAL 50 MG POWDER FOR DISPERSION FOR INFUSION

Gilead Sciences Ltd has informed us of a quality defect issue, in relation to specific lots of 5µm sterile filters, which are co-packed in cartons of the AmBisome product. The medical device is called Minisart Filter 16534-K

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-ambisome-liposomal-50-mg-powder-for-dispersion-for-infusion-pl-16807-slash-0001-el-21-a-slash-03?utm_medium=email&utm_campaign=govuk-notifications&utm_source=b511116a-dcc6-4c20-ab3a-38f79ce58479&utm_content=immediately

Alliance healthcare do not stock this product therefore we are not accepting stock returns.

For more information or medical information queries, please contact:

Gilead Sciences Ltd Medical Information Telephone: +44 (0) 8000 113700 E-mail: ukmedinfo@gilead.com

For stock control queries, please contact:

Customer Care direct line: +44 (0)203 681 4681 E-mail: UKCustomer.Services@gilead.com

CLASS 2 RECALL - PALEXIA ORAL SOLUTION 20MG/1ML

Grünenthal Ltd has informed us of a potential microbial contamination during routine stability testing for the batches listed in this recall. Due to the detection of possible Burkholderia contaminans the batches listed are being recalled as a precautionary measure. Burkholderia contaminans is a gram-negative bacterium and any potential infection may be more serious for immunocompromised patients and patients suffering from cystic fibrosis. This recall affects all batches of oral solution in the UK market that are still within their expiry date

This product is a Schedule 2 Controlled Drug, so please use the Returns Portal for any recalled stock you may need to return to ensure there is authorisation to return. If you are unable to use the Returns Portal please call Customer Services for assistance.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-grunenthal-ltd-palexia-20-mg-slash-ml-oral-solution-pl-21727-slash-0054?utm_medium=email&utm_campaign=govuk-notifications&utm_source=ec81d6b3-a9c2-4242-ad66-27309a75a6fb&utm_content=immediately  

Further Information

For more information or medical information queries please contact +44 (0) 870 351 8960

medicalinformationuk@grunenthal.com

Grünenthal Ltd,1 Stokenchurch Business Park Ibstone Road HP14 3FE

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 08/05/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

CLASS 3 RECALL - KOLANTICON GEL 500ML

Intrapharm Laboratories Ltd has received a number of complaints that the product consistency is lumpy. The investigation has confirmed through review of the retained samples that the consistency of the complaint samples are similar and the retained samples for this batch show the same homogeneity issue

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-intrapharm-laboratories-ltd-kolanticon-gel-500ml-el-21-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications&utm_source=1c3cadd1-c259-4e77-b3e8-c13faf584fe2&utm_content=immediately  

For more information or medical information queries, please contact: medinfo@intrapharmlabs.com or telephone +44 (0)330 1359 437.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

FIELD SAFTEY NOTICE - BD SYRINGES AND NEEDLES

BD has become aware that when syringes and needles are used for intraocular injections, the potential exists for “floaters” in patients’ eyes which are believed to be due to silicone. (Note: Syringes and needles manufactured by BD have silicone applied to the inside of the barrels to provide lubrication for the plunger stopper, allowing it to move easily). The potential hazard is deposition of silicone oil (SO) droplets in the vitreous.  The potential harm could be symptomatic “floaters” in the patient’s field of vision which, normally, are tolerable and resolve over a few months.  However, if sufficiently bothersome, floaters may lead to a vitrectomy for their removal

MHRA drug alert link: N/A              

This field safety notice is Advisory only so Alliance Healthcare are not accepting stock returns.

Should you have any questions or experience any issues associated with the product or issue described in this Field Safety Notice, please contact BDUKFieldAction@bd.com. BD has notified the appropriate regulatory agencies of these actions.

COMPANY-LED DRUG ALERT - RESPREEZA 1,000 MG POWDER AND SOLVENT FOR SOLUTION FOR INFUSION

CSL Behring UK Ltd is recalling the below batches of Respreeza 1,000 mg powder and solvent for solution for infusion (EU/1/15/1006/001) due to a manufacturing deviation that occurred during the filling process. There is a risk of potential microbial contamination due to the failure of the HEPA filters at the manufacturing site and the batches are being recalled as a precautionary measure. This product is only supplied to Pharmacies and/or Hospitals Pharmacies and not to wholesale, via our 3PL partner Alloga UK Ltd

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-respreeza-1000-mg-powder-and-solvent-for-solution-for-infusions-eu-slash-1-slash-15-slash-1006-slash-001?utm_medium=email&utm_campaign=govuk-notifications&utm_source=ea5d64be-6beb-4a4b-b8a9-a24edc5aeea8&utm_content=immediately              

Alliance do not stock this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Jo Heaton (Head of Medical Affairs UK & Ireland, Commercial Operations United Kingdom) CSL Behring UK Ltd by emailing: Jo.Heaton@cslbehring.com

Company Contact for stock enquiries

For stock information enquiries, please contact: Karien Pietersen (Head of Quality) CSL Behring UK Ltd by emailing: Karien.pietersen@cslbehring.com

COMPANY-LED DRUG ALERT - INSTANYL 100MCG SINGLE DOSE

Takeda UK Limited is recalling the below batch of Instanyl 100mcg nasal spray solution (EU/1/09/531/015) due to the observation of cracked vials during inspection of the bulk vials and release testing of the finished products. So far, the company has not received any reports of damage for the marketed products. However, due to the low potential for breaking or cracking of the glass vial, which is contained within the plastic actuator casing and a potential risk of microbial contamination, the above batch is being recalled as a precautionary measure

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-instanyl-100mcg-nasal-spray-solution-eu-slash-1-slash-09-slash-531-slash-015?utm_medium=email&utm_campaign=govuk-notifications&utm_source=a6ea9305-5a64-4dd6-ae86-912f9bbbe915&utm_content=immediately         

Alliance have not supplied this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Takeda UK Limited by emailing medinfoemea@takeda.com

Company Contact for stock enquiries

Remaining stock of these batches should be quarantined and returned to Takeda for replacement stock where available.

For stock information enquiries, please contact: Alloga UK by emailing allogaUK.credit.claims@alloga.co.uk